StocktoriaJUPITER NEUROSCIENCES, INC. JUNS
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
2/9
Piotroski F — financial health
—
Altman Z″ — distress risk
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Financials | |||
| Revenue | $21,796 | $0 | — |
| Gross profit | $17,565 | — | — |
| Operating income | -$8.9M | -$3.1M | -$3.9M |
| Net income | -$8.6M | -$2.4M | -$4.8M |
| Operating cash flow | -$5.4M | -$3.9M | -$480,953 |
| Total assets | $5.6M | $6.2M | $148,592 |
| Total liabilities | $7.4M | $2.0M | $5.9M |
| Shareholders' equity | -$1.8M | $4.2M | -$5.8M |
| Ratios | |||
| Gross margin | 80.6% | — | — |
| Operating margin | -40873.2% | — | — |
| Net margin | -39662.8% | — | — |
| Return on assets | -155.4% | -39.3% | -3219.3% |
| Return on equity | 471.9% | -58.5% | 82.5% |
| Current ratio | 0.65 | 2.31 | 0.00 |
Why these scores methodology →
Piotroski F-score: 2/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: n/a
Not applicable (financials/insurer or missing inputs).
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001679628 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.